Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | TOP2A | P11388 | 1/20 | 0.58 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | FGB | P02675 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102055 | 0.94 | ALDH1A1 (0.64) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL1102099 | 0.91 | PKM (0.57) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL1102018 | 0.91 | TOP2A (0.56) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL1102111 | 0.89 | MAPT (0.63) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL1102053 | 0.86 | MAPT (0.69) | SMN1; SMN2MAPTPOLBALDH1A1RECQL | |
| SCHEMBL1102262 | 0.81 | MEN1 (0.79) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL17444745 | 0.78 | BACE1 (0.66) | SMN1; SMN2MAPTPOLBTOP2ATOP2B | |
| SCHEMBL1102056 | 0.77 | POLB (0.60) | SMN1; SMN2MAPTPOLBALDH1A1RECQL | |
| SCHEMBL1102261 | 0.76 | MAPT (0.71) | MAPTPOLBALDH1A1RECQLMEN1 | |
| SCHEMBL9972263 | 0.76 | SCN3A (0.60) | SMN1; SMN2MAPTALDH1A1RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | SMN1; SMN2 524/4885MAPT 1883/4885POLB 4241/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | SMN1; SMN2 524/4885MAPT 1883/4885POLB 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.